← Back to headlines
Fulcrum Therapeutics Stock Plunges After Discontinuing Lead Program
Fulcrum Therapeutics' stock plunged after the company announced the discontinuation of its lead program, impacting investor confidence.
2 Jun, 10:58 — 2 Jun, 10:58
Sources
Showing 1 of 1 sources
